Connect your agent to akta.pro and build company lists like this across sectors and geos.
US-headquartered biotechnology companies with newly reported CFO appointments in Q3 2026, ranked by appointment announcement date. Explore executive changes alongside company profiles, industry classifications, estimated revenue, funding information and linked news sources.
Tortugas Neuroscience appointed Ramzi Benamar as Chief Financial Officer on Sep 25, 2026, with 1 distinct source attached to the normalized LG01 event.
2 of 15 ranked companies fall into Oncology & Hematology Pharmaceuticals, based on the primary industry returned by akta.pro Company Data rather than article wording.
13 of 15 displayed appointments classify primarily as Finance & Capital; 0 are explicitly described by sources as first-of-kind or newly created roles.
| # | Date | Company | Industry / category | Firmographics | Est. revenue | Funding | Executive appointment | Mandate | Sources |
|---|---|---|---|---|---|---|---|---|---|
| 01 | Sep 25, 2026 | Tortugas Neuroscience↗ Private · Venture Growth Investor Backed | Neurology & CNS Specialty Pharmaceuticals Healthcare & Life Sciences Pharmaceuticals | Framingham, US Founded 2026 · 1-10 emp. | Pre-revenue | $106M | Ramzi Benamar Chief Financial Officer | Finance & Capital Brings experience in capital formation, corporate strategy, M&A, operational scaling and commercial launch preparation. | The Pharma Letter 1 source |
| 02 | Sep 10, 2026 | SCYNEXIS↗ Public · Public | Rare Renal & Nephrology Disorder Therapies Healthcare & Life Sciences Pharmaceuticals | Jersey City, US Founded 2000 · 11-50 emp. | $10M-$25M | $319M | Sanjay Subramanian Chief Financial Officer | Finance & Capital Takes the CFO role effective September 9, 2026, with Ivor Macleod retiring from it. | Stock Titan 1 source |
| 03 | Sep 9, 2026 | Starton Therapeutics↗ Private · Founder Individual Operated Bootstrapped | Oncology & Hematology Pharmaceuticals Healthcare & Life Sciences Pharmaceuticals | Paramus, US Founded 2017 · 11-50 emp. | Pre-revenue | $10.7M | Saleem Elmasri Chief Financial Officer | Finance & Capital Succeeds Scott Kahn and supports the upcoming company milestones. | BioSpace 1 source |
| 04 | Sep 8, 2026 | Alterome Therapeutics↗ Private · Venture Growth Investor Backed | Oncology Pathways & Precision Medicine Decision Support Healthcare & Life Sciences Digital Health & Health IT | San Diego, US Founded 2022 · 11-50 emp. | Pre-revenue | $231M | Johanna Mylet Previously Finance executive · Poseida Therapeutics Chief Financial Officer | Finance & Capital Oversees financial strategy and capital formation; joins from Poseida Therapeutics. | citybiz 1 source |
| 05 | Sep 8, 2026 | Flare Therapeutics↗ Private · Venture Growth Investor Backed | Drug Discovery (Target ID/Validation & Hit Discovery) Healthcare & Life Sciences Pharmaceuticals | Cambridge, US Founded 2021 · 51-100 emp. | Pre-revenue | $290M | Brian DeSchuytner Chief Financial Officer and Chief Business Officer | Hybrid Brings finance and business strategy experience to support advancing the pipeline. | BioSpace 1 source |
| 06 | Sep 8, 2026 | Kura Oncology↗ Public · Public | Oncology & Hematology Pharmaceuticals Healthcare & Life Sciences Pharmaceuticals | San Diego, US Founded 2014 · 251-500 emp. | $50M-$100M | $1.2B | Jennifer Fulk Previously CFO · Soleno Therapeutics Chief Financial Officer | Finance & Capital Reports to CEO Troy Wilson; previously CFO at Talkspace, 120Water and Soleno Therapeutics. | Stock Titan 1 source |
| 07 | Sep 8, 2026 | Sparrow Pharmaceuticals↗ Private · Venture Growth Investor Backed | Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity) Healthcare & Life Sciences Pharmaceuticals | Boston, US Founded 2021 · 1-10 emp. | Pre-revenue | $156M | George Eldridge Chief Financial Officer | Finance & Capital Brings over two decades of biotech financial leadership and previously guided Abcuro and Aerovate through IPOs. | BioSpace 1 source |
| 08 | Sep 3, 2026 | LB Pharmaceuticals↗ Public · Public | Neurology & Psychiatry (CNS) Pharmaceuticals Healthcare & Life Sciences Pharmaceuticals | New York, US Founded 2015 · 101-250 emp. | Pre-revenue | $383M | Joseph Miller Previously CFO · Avalo Therapeutics Chief Financial Officer | Finance & Capital Leads financial strategy; previously CFO of Aurinia Pharmaceuticals and Avalo Therapeutics. | Stock Titan 1 source |
| 09 | Sep 1, 2026 | Vertex Pharmaceuticals↗ Public · Public | Stem Cell Therapies (MSC/iPSC/HSC-derived) Healthcare & Life Sciences Biotechnology & Biologics | Boston, US Founded 1989 · 5001-10000 emp. | $5B+ | $5.2B | Jonathan Poole Executive Vice President and Chief Financial Officer | Finance & Capital Takes the CFO role effective Jan. 1, 2027 in connection with the Crinetics acquisition. | MarketScreener 1 source |
| 10 | Aug 27, 2026 | Outlook Therapeutics↗ Public · Public | Ophthalmology Pharmaceuticals Healthcare & Life Sciences Pharmaceuticals | Iselin, US Founded 2015 · 11-50 emp. | $1M-$5M | $437M | Kevin Lundquist Chief Financial Officer | Finance & Capital Named CFO on September 1 as the company prepares for the U.S. launch of LYTENAVA. | Investing.comStock Titan +2 more 4 sources |
| 11 | Aug 27, 2026 | Alto Neuroscience↗ Public · Public | Neurology & Psychiatry (CNS) Pharmaceuticals Healthcare & Life Sciences Pharmaceuticals | Mountain View, US Founded 2019 · 51-100 emp. | Pre-revenue | $521M | Nick Smith President and Chief Financial Officer | Hybrid Promoted to President and CFO. | Stock TitanMarketScreener 2 sources |
| 12 | Aug 25, 2026 | Cleveland Diagnostics↗ Private · Venture Growth Investor Backed | Oncology Diagnostics (tumor profiling, MRD, liquid biopsy) Healthcare & Life Sciences Biotechnology & Biologics | Cleveland, US Founded 2013 · 101-250 emp. | $5M-$10M | $125M | Valerie Dixon Previously Finance executive · Flagship Pioneering Chief Financial Officer | Finance & Capital Brings 20 years of healthcare investment banking and strategic finance experience, including Morgan Stanley and Flagship Pioneering. | citybiz 1 source |
| 13 | Aug 24, 2026 | Tempest Therapeutics↗ Public · Public | CAR-T & TCR-T Therapies Healthcare & Life Sciences Biotechnology & Biologics | Brisbane, US Founded 2011 · 11-50 emp. | Pre-revenue | $114M | Nicholas Rossettos Chief Financial Officer and Principal Financial and Accounting Officer | Finance & Capital Appointment effective September 1, 2026, disclosed in an SEC filing. | AInvest 1 source |
| 14 | Aug 19, 2026 | Sera Prognostics↗ Public · Public | Prenatal, Newborn & Reproductive Diagnostics (NIPT, IVF/PGT, newborn screening) Healthcare & Life Sciences Biotechnology & Biologics | Salt Lake City, US Founded 2008 · 51-100 emp. | Under $1M | $306M | Scott Gleason Chief Financial Officer | Finance & Capital Named CFO of the women health diagnostics company. | Seeking AlphaMarketScreener +1 more 3 sources |
| 15 | Aug 19, 2026 | Longeveron↗ Public · Public | Cell Therapy Developers (Allogeneic/Off-the-shelf) Healthcare & Life Sciences Biotechnology & Biologics | Miami, US Founded 2014 · 11-50 emp. | Pre-revenue | $69.0M | Nirav Jhaveri Chief Financial Officer | Finance & Capital Succeeds Marie Washburn, who returns to the role of Corporate Controller. | Stock TitanSeeking Alpha 2 sources |
A company qualifies when a named executive is appointed or promoted to CFO during Q3 2026, supported by reporting that identifies the role and appointment. The ranking uses the announcement date and includes one row per company.
Company geography and industry are based on the company profile, not the news publisher location. Where multiple articles describe one appointment, those sources are grouped under the same company.
Companies are tagged against standard industry codes and against akta.pro’s internal taxonomy, so the same set can be rebuilt by code, by segment, or by a combination of both.
NAICSIndustry codes are provided for cross-referencing against public filings and procurement records. akta.pro classification is independent of them, so a company may carry an internal segment without a matching NAICS or SIC registration.